New global data on 5-year prostate cancer survival

A new study by Allemani et al., just published in The Lancet, has provided us with data from the largest ever global study of cancer survival, encompassing nearly 26 million people in 279 population-based registries from 67 countries around the world. … READ MORE …

Is treatment with degarelix really “better” than treatment with an LHRH agonist?

One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …

The dangers of using nomograms to compare apples to oranges

A cross-specialty group of prostate cancer experts has reviewed data from > 13,000 patients on the accuracy of nomograms in predicting biochemical recurrence and actual prostate cancer-specific mortality after three different types of treatment. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …

Cancer drugs that don’t extend survival

An article by John Fauber in this Sunday’s issue of the Milwaukee Journal-Sentinel has been receiving a lot of attention in the oncology news over the past 48 hours. The title of this article is “FDA approves cancer drugs without proof they’re extending lives.” … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

Data from two large cohorts of Austalian patients on active surveillance

A new paper in BJU International reports on data from a total of 650 Australian patients managed on active surveillance for low-risk, localized prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,181 other followers